CTOs on the Move

Vascular Technology

www.vti-online.com

 
Vascular Technology Incorporated is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Nipro Medical

Nipro provides premium renal medical devices, including dialyzers, bloodlines, AVF needles, as well as high-quality medical surgical products.

EMSAR

You can depend on us. Our mission is to provide quality equipment services and repairs to our valued customers across the U.S. and Canada.

Portions Master

Portions Master is a company that specializes in unique, scientifically validated products and supplements that help achieve and maintain a lean lifestyle. Their focus is to offer quality products and supplements to make it as easy as possible for thei...

Boone Drug At New Market

Boone Drug and Healthcare at Deerfield offers a broad range of retail pharmacy, home medical equipment, prosthetic and orthotic goods, home respiratory care, post mastectomy fitters services, enteral therapy services to fill the medical and convalescent

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.